Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia
Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML
|3||Active, not recruiting||
Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase
† Study has passed its completion date and status has not been verified in more than two years.